Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment

Purpose of ReviewExtrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare, aggressive malignancy that can arise from any organ and frequently presents with distant metastases. Advanced disease has a poor prognosis with median overall survival (OS) rarely exceeding 1 year even with systemic therapy. The management paradigm of advanced/metastatic EP-NEC has been extrapolated from small cell lung cancer (SCLC) and commonly consists of 1st line therapy with etoposide and platinum (cisplatin or carboplatin), followed by alternative cytotoxic regimens at the time of progression. Only a minority of patients are able to receive 2nd line therapy, and cytotoxics derived from the SCLC paradigm such as topotecan or lurbinectedin have very limited activity. We aimed to evaluate emerging therapeutic options in the 2nd and later lines and survey potential future developments in this space.Recent FindingsAfter a long period of stagnation in treatment options and outcomes, more promising regimens are gradually being utilized in the 2nd line setting including systemic therapy combinations such as FOLFIRI, FOLFOX, modified FOLFIRINOX, CAPTEM, and, more recently, novel checkpoint inhibitors such as nivolumab and ipilimumab. Simultaneously, advances in the understanding of disease biology are helping to refine patient selection and identify commonalities between NEC and their sites of origin which may eventually lead to additional targeted therapy options.While many questions remain, contemporary developments give grounds for optimism that improved outcomes for EP-NEC will soon be within reach.

Automated summary

This review evaluates the second-line and later therapeutic options for extrapulmonary neuroendocrine carcinoma (EP-NEC) and explores potential future developments. Promising regimens, such as systemic therapy combinations and novel checkpoint inhibitors, are gradually being utilized in the second-line setting. Advances in understanding disease biology are also helping to refine patient selection and identify targeted therapy options. While there are still many questions to be answered, contemporary developments provide grounds for optimism regarding improved outcomes for EP-NEC.